14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CALA ranks #15927 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Calithera Biosciences Stock Forecast NASDAQ:CALA

$0.50 (-7.00%)

Volume: 501k

Closed: Jan 18, 2022

Hollow Logo Score: -7.656

Calithera Biosciences Stock Forecast

$0.50 (-7.00%)

Volume: 501k

Closed: Jan 18, 2022

Score Hollow Logo -7.656

Calithera Biosciences Company Profile

343 Oyster Point Boulevard

South San Francisco CA 94080



Industry: Biotechnology

Sector: Healthcare

Calithera Biosciences


Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE